A more efficient system using archived specimens for the evaluation of prognostic and predictive biomarkers has been proposed by researchers in a new commentary published online October 8 in the Journal of the National Cancer Institute.
The introduction of new biomarkers into routine use in clinical laboratories has been limited partly because of a shortage of prospective studies of marker utility, a lack of reproducibility and reliability among retrospective studies, and low insurance reimbursements for tumor marker tests. In the case of biomarkers for guiding the use of already approved drugs, new prospective studies are sometimes not possible.
Richard M. Simon, DSc, of the Biometric Research Branch at the National Cancer Institute in Bethesda, Md., and colleagues discuss more efficient ways for indirectly testing biomarkers using archived patient tissue specimens, arguing they can be of "great importance for establishing a medical utility of a prognostic or predictive biomarker."
"It is essential to ensure that cancer patients are offered the benČefits of valuable prognostic and predictive tests as soon as they are rigorously and reliably evaluated," the authors write. "In this article, we have tried to...propose an update of a level of evidence schema that has been widely used for evaluČating... biomarkers in oncology."